mosapride
Small moleculeexperimental
Clinical trial activity
33 trials · 32 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
13
Phase 3
9
Phase 4
8
Earliest trial started May 1, 2008 (NCT00663897)
Timeline
Indications
Approved for
Studied for
- Colorectal Neoplasms · Phase 4
- Constipation · Phase 4
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diarrhea · Phase 1
- Dyspepsia · Phase 4
- Endoscopy · Phase 3
- Enteral Nutrition · Phase 3
- Gastritis · Phase 1
- Gastroesophageal Reflux · Phase 4
- Gastrointestinal Diseases · Phase 1/Phase 2
- Healthy Volunteers · Phase 4
- Intestinal Neoplasms · Phase 2
- Irritable Bowel Syndrome · Phase 4
- Medicine, Chinese Traditional · Phase 1/Phase 2
- Pain · Phase 4
- Postoperative Complications · Phase 4
- Psychological Distress · Phase 4
- Therapeutic Equivalency · Phase 1
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
- Serotonin 3 (5-HT3) receptorANTAGONIST
Serotonin 3 (5-HT3) receptor antagonist
Through an active metabolite
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1.O=C(O)CC(O)(CC(=O)O)C(=O)O- Mol. weight
- 614.02 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL60889 ↗
- ChEMBLCHEMBL1733174 ↗
Also known as
- 4-amino-5-chloro-2-ethoxy-n-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide
- as 4370
- as 4370
- as 4370
- as 4370
- as 4370
- as-4370
- as-4370
- benzamide, 4-amino-5-chloro-2-ethoxy-n-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
- gasmotin
- gasmotin
- mosapride
- mosapride
- mosapride
- mosapride
- mosapride
- mosapride
- mosapride
- mosapride citrate
- mosapride citrate
- mosapride citrate
- mosapride citrate
- mosapride (citrate)
- mosapride (citrate)
- mosapride citrate dihydrate
- mosapride citrate hydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07096921 | N/A | Jul 8, 2025 | Catholic University of Korea, Daewoong Pharmaceutical Co. LTD., Dong-A Pharmaceutical, Eunpyeong St. Mary's Hospital |
| NCT06826443 | Phase 3 | Feb 28, 2025 | Ain Shams University |
| NCT06782594 | Phase 2 | Oct 18, 2024 | Shandong New Time Pharmaceutical Co., LTD |
| NCT06481371 | N/A | Jun 30, 2024 | Nanjing Medical University |
| NCT05720442 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2023 | China Academy of Chinese Medical Sciences |
| NCT06156995 | N/A | Jan 1, 2023 | Shandong Province Qianfoshan Hospital |
| NCT04905147 | N/A | Jul 1, 2021 | Mahidol University |
| NCT04493125 | N/A | Jul 27, 2020 | Yonsei University |
| NCT04350346 | N/A | Mar 25, 2020 | Yonsei University |
| NCT03477266 | Phase 3 | Apr 1, 2018 | Benha University |
| NCT03040817 | N/A | Jun 16, 2017 | Southeast University |
| NCT03149393 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | China Academy of Chinese Medical Sciences, Xiyuan Hospital |
| NCT03184402 | Phase 3 | Apr 24, 2017 | Daewoong Pharmaceutical Co. LTD., Seoul National University |
| NCT03024086 | Phase 3 | Dec 1, 2016 | Daewoong Pharmaceutical Co. LTD. |
| NCT02831543 | Phase 3 | Apr 1, 2016 | IlDong Pharmaceutical Co Ltd, Seoul National University |
| NCT02606617 | Phase 4 | Dec 1, 2015 | People's Liberation Army of China |
| NCT02056405 | Phase 4 | Dec 1, 2015 | Hospital Italiano de Buenos Aires |
| NCT02433847 | Phase 4 | May 1, 2015 | Seoul National University |
| NCT03225248 | Phase 3 | Nov 5, 2014 | Korea United Pharm. Inc. |
| NCT02264587 | Phase 4 | Oct 1, 2014 | Qingdao University, Sumitomo |
Showing 20 of 33 trials
Page 1 / 2
Organizations
Research & Development (32)
32 organizations
Page 1 / 2